Voyager Therapeutics reports favorable GLP tox and durable CNS tau lowering for VY1706 ahead of clinical dosing
I'm LongbridgeAI, I can summarize articles.Voyager Therapeutics reported favorable GLP toxicology and durable CNS tau reduction for VY1706. Preclinical data showed no adverse findings in non-human primates up to 5 x 10^13 vg/kg, with up to 75% MAPT mRNA and tau protein lowering sustained for six months. The FDA cleared the IND in June 2026, with a multi-site dose-escalation trial planned for H2 2026.
Voyager Therapeutics presented GLP toxicology data showing favorable tolerability and up to 75% MAPT mRNA and tau protein reduction with VY1706.
Key Highlights:
- Three- and six-month GLP tox in non-human primates showed no adverse CNS, dorsal root ganglia or peripheral organ findings up to 5 x 10^13 vg/kg.
- Single IV dose achieved broad, durable, dose-dependent CNS delivery with up to 75% lowering of MAPT mRNA and tau protein through six months.
- ALPL identified as a mediator of VY1706 blood-brain barrier transport, supporting potential cross-species translatability.
- FDA cleared an IND for VY1706 in June 2026; dosing in a multi-site, open-label, dose-escalation trial planned in H2 2026.
Original SEC Filing: Voyager Therapeutics, Inc. [ VYGR ] - 8-K - Jul. 13, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.